GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » Cyclically Adjusted Revenue per Share

HLB Therapeutics Co (XKRX:115450) Cyclically Adjusted Revenue per Share : ₩759.57 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

HLB Therapeutics Co's adjusted revenue per share for the three months ended in Mar. 2024 was ₩173.043. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩759.57 for the trailing ten years ended in Mar. 2024.

During the past 12 months, HLB Therapeutics Co's average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of HLB Therapeutics Co was -10.90% per year. The lowest was -11.50% per year. And the median was -11.20% per year.

As of today (2024-05-26), HLB Therapeutics Co's current stock price is ₩8190.00. HLB Therapeutics Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₩759.57. HLB Therapeutics Co's Cyclically Adjusted PS Ratio of today is 10.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HLB Therapeutics Co was 18.17. The lowest was 3.65. And the median was 6.61.


HLB Therapeutics Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for HLB Therapeutics Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co Cyclically Adjusted Revenue per Share Chart

HLB Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,125.79 1,091.47 1,059.81 780.52 771.80

HLB Therapeutics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 727.52 715.61 681.90 771.80 759.57

Competitive Comparison of HLB Therapeutics Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, HLB Therapeutics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Therapeutics Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's Cyclically Adjusted PS Ratio falls into.



HLB Therapeutics Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HLB Therapeutics Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=173.043/118.8477*118.8477
=173.043

Current CPI (Mar. 2024) = 118.8477.

HLB Therapeutics Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 100.526 99.353 120.251
201409 110.325 99.608 131.635
201412 110.746 99.098 132.817
201503 215.574 99.720 256.924
201506 93.272 100.050 110.796
201509 93.377 100.110 110.854
201512 114.323 100.220 135.572
201603 109.141 100.560 128.989
201606 86.888 100.790 102.455
201609 102.606 101.460 120.190
201612 79.391 101.560 92.905
201703 91.767 102.850 106.041
201706 82.897 102.610 96.015
201709 125.653 103.490 144.300
201712 73.692 102.990 85.039
201803 87.248 104.100 99.608
201806 72.331 104.130 82.554
201809 428.109 105.650 481.588
201812 283.854 104.350 323.291
201903 175.264 104.490 199.347
201906 171.588 104.880 194.440
201909 402.892 105.200 455.160
201912 430.483 105.120 486.700
202003 175.271 105.540 197.371
202006 131.481 104.870 149.006
202009 185.030 106.200 207.066
202012 271.581 105.765 305.173
202103 125.625 107.357 139.071
202106 96.794 107.579 106.933
202109 324.724 108.759 354.845
202112 197.570 109.676 214.091
202203 160.769 111.806 170.895
202206 77.290 114.083 80.518
202209 366.898 114.831 379.731
202212 110.885 115.200 114.396
202303 184.133 116.550 187.764
202306 118.384 117.140 120.110
202309 263.942 119.111 263.358
202312 234.854 118.848 234.854
202403 173.043 118.848 173.043

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


HLB Therapeutics Co  (XKRX:115450) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HLB Therapeutics Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8190.00/759.57
=10.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HLB Therapeutics Co was 18.17. The lowest was 3.65. And the median was 6.61.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


HLB Therapeutics Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Therapeutics Co (XKRX:115450) Business Description

Industry
Traded in Other Exchanges
N/A
Address
22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co (XKRX:115450) Headlines

No Headlines